Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456562 | 0.96 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL18660235 | 0.93 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL4849446 | 0.89 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2546574 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL8951934 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5612643 | 0.87 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17748427 | 0.87 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17014892 | 0.86 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6879979 | 0.86 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL11992613 | 0.86 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009058852-A2 | MINOR GROOVE BINDER-ENERGY TRANSFER OLIGONUCLEOTIDES AND METHODS FOR THEIR USE | EPOCH BIOSCIENCES, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111100-A1 | MINOR GROOVE BINDER - ENERGY TRANSFER OLIGONUCLEOTIDES AND METHODS FOR THEIR USE | ELITECH HOLDING B.V. (NL) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111100-A1 | MINOR GROOVE BINDER - ENERGY TRANSFER OLIGONUCLEOTIDES AND METHODS FOR THEIR USE | SSBP1, SNRPE, TARBP1 | SLC28A1 719/4885SLC28A2 872/4885SLC29A1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.